

Ifw

Atty. Docket No.: 18396/2282

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Friedler, et al.  
Serial No.: 10/775,679  
Filed: February 10, 2004  
Entitled: Stabilizing Molecule

Examiner: Not yet assigned  
Group Art Unit: 1644  
Conf. No.: 1897

**CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a**

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Mary Wilson

Name of Person Mailing Paper

Signature of Person Mailing Paper

**Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450**

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§ 1.56, 1.97 AND 1.98**

Dear Sir:

In accordance with the duty of disclosure under 37 CFR § 1.56, Applicant submits this Information Disclosure Statement pursuant to 37 CFR §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office.

A listing of the cited documents is also enclosed, as well as, for the Examiner's convenience, copies of the documents in the list.

Pursuant to CFR § 1.97(b)(3), because this Statement is being submitted before the first Office Action on the merits, no fee is required.

Applicant does not intend to represent that any of the documents submitted herein are material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicant respectfully requests that the documents submitted herein be considered and made of record in this application.

Date:

9/2/04

Respectfully submitted,

Name: Mark J. FitzGerald

Registration No.: 45,928


Customer No.: 29933

Palmer & Dodge LLP

111 Huntington Avenue

Boston, MA 02199-7613

Tel: 617-239-0100



Atty. Docket No.: 18396/2282

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Friedler, et al.  
Serial No.: 10/775,679  
Filed: February 10, 2004  
Entitled: Stabilizing Molecule

Examiner: Not yet assigned

Group Art Unit: 1644

Conf. No.: 1897

**CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a**

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Mary Wilson

Name of Person Mailing Paper

Signature of Person Mailing Paper

**Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450**

**TRANSMITTAL LETTER**

Enclosed for filing in the above-identified patent application, please find the following documents:

1. Supplemental Information Disclosure Statement;
2. Form PTO-1449;
3. Copies of Cited References; and
4. Return Post Card.

The Commissioner for Patents is hereby authorized to charge any fees to Deposit Account No. 16-0085, Reference 18396/2282. A duplicate of this transmittal letter is enclosed for this purpose.

Respectfully submitted,

Date:

9/2/04

Name: Mark J. FitzGerald

Registration No.: 45,928


Customer No.: 29933

Palmer & Dodge LLP

111 Huntington Avenue

Boston, MA 02199-7613

Tel: 617-239-0100



|   |    |  |                  |                                   |                 |                          |                              |
|---|----|--|------------------|-----------------------------------|-----------------|--------------------------|------------------------------|
| USPTO Form 1449 U.S. Department of Commerce<br>Patent and Trademark Office  |    |  |                  | Attorney Docket No.<br>18396/2282 |                 | Serial No.<br>10/775,679 |                              |
| INFORMATION DISCLOSURE STATEMENT  |    |  |                  | Applicant(s): Friedler, et al.    |                 |                          |                              |
|   |    |  |                  | Filing Date: February 10, 2004    |                 | Group: Not yet assigned  |                              |
| U.S. PATENT DOCUMENTS   |    |  |                  |                                   |                 |                          |                              |
| Examiner Initial  |    | Patent No.   | Date             | Name                              | Class           | Subclass                 | Filing Date (if appropriate) |
| FOREIGN PATENT DOCUMENTS  |    |  |                  |                                   |                 |                          |                              |
| Examiner Initial  |    | Document No.   | Publication Date | Country                           | Class           | Subclass                 | Translation                  |
|   |    |  |                  |                                   |                 | YES                      | NO                           |
| OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)  |    |  |                  |                                   |                 |                          |                              |
|   | 1. | Cho, et al., "Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations", Science (1994), V. 265, Pages 346-355.  |                  |                                   |                 |                          |                              |
|   | 2. | Selivanova, et al., "Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain", Nature Medicine (1997), V. 3, Pages 632-638.             |                  |                                   |                 |                          |                              |
|   | 3. | Bullock, et al., "Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy", Oncogene (2000), V. 19, Pages 1245-1256. |                  |                                   |                 |                          |                              |
|   | 4. | Abarzua, et al., "Restoration of the transcription activation function to mutant p53 in human cancer cells", Oncogene (1996), V. 13, Pages 2477-2482.  |                  |                                   |                 |                          |                              |
|   | 5. | Hainaut, et al., "p53 and human cancer: the first ten thousand mutations", Advances in Cancer Research (2000), V. 77, Pages 81-137.  |                  |                                   |                 |                          |                              |
|   | 6. | Hupp, et al., "Small peptides activate the latent sequence-specific DNA binding function of p53", Cell (1995), V. 83, Pages 237-245.   |                  |                                   |                 |                          |                              |
|   | 7. | Hupp, et al., "Strategies for manipulating the p53 pathway in the treatment of human cancer", Biochemical Journal (2000), V. 352, Pages 1-17.  |                  |                                   |                 |                          |                              |
|   | 8. | Sigal, et al., "Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome", Cancer Research (2000), V. 60, Pages 6788-6793.  |                  |                                   |                 |                          |                              |
|   | 9. | Selivanova, et al., "Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain", Molecular and Cellular Biology (1999), V. 19, Pages 3395-3402.                          |                  |                                   |                 |                          |                              |
| EXAMINER  |    |  |                  |                                   | DATE CONSIDERED |                          |                              |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. |    |  |                  |                                   |                 |                          |                              |
| **Copies of references not provided at the time of this submission.   |    |  |                  |                                   |                 |                          |                              |